Study on the Diagnostic Value of Multi-omics Combined Detection for Precancerous Lesions of CRC
Study on the Diagnostic Value of Multi-omics Combined Detection for Precancerous Lesions of Colorectal Cancer
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Zhaoshen Li, M.D
- Phone Number: +86-021-31161365
- Email: li.zhaoshen@hotmail.com
Study Contact Backup
- Name: Yu Bai, M.D
- Phone Number: +86-021-31161335
- Email: baiyu1998@hotmail.com
Study Locations
-
-
-
Shanghai, China, 200433
- Recruiting
- Changhai Hospital, Naval Medical University
-
Contact:
- Yu Bai, M.D.
- Phone Number: +86-021-81873241
- Email: baiyu1998@hotmail.com
-
Contact:
- Yihang Song, M.D.
- Phone Number: +86-021-31162770
- Email: noah_ir77@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients whose age is between 18-75.
- Patients who have signed informed consent form.
Exclusion Criteria:
- Patients who have undergone colonic resection or polypectomy.
- Patients with abnormal blood coagulation or taking antiplatelets or anticoagulants within 7 days.
- Patients with hereditary colorectal cancer syndrome (including familial adenomatous polyposis).
- Patients with pregnancy, severe chronic cardiopulmonary and renal disease.
- Patients with failed cecal intubation.
- Patients with poor BPQ necessitated a second bowel preparation.
- Patients refusing to participate or to provide informed consent
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Control
Volunteers with no significant abnormalities on colonoscopy were given informed consent to obtain colon tissue biopsies and fecal specimens.
|
|
Non-advanced adenoma
Patients with non-advanced adenoma were given informed consent to obtain colon tissue biopsies and fecal specimens.
|
|
Advanced adenoma
Patients with advanced adenoma were given informed consent to obtain colon tissue biopsies and fecal specimens.
|
|
Inflammatory bowel disease
Patients with inflammatory bowel disease were given informed consent to obtain colon tissue biopsies and fecal specimens.
|
|
Colorectal cancer
Patients with colorectal cancer were given informed consent to obtain cancer tissue biopsies and fecal specimens.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Detection of advanced colorectal adenoma
Time Frame: Through study completion, an average of 1 year
|
An advanced colorectal adenoma is defined as a colorectal adenoma ≥10 mm, adenoma with tubulovillous or villous histology, or adenoma with high-grade dysplasia
|
Through study completion, an average of 1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Detection of colorectal cancer
Time Frame: Through study completion, an average of 1 year
|
Lesions will be confirmed as malignant by histopathologic examination.
|
Through study completion, an average of 1 year
|
|
Detection of non-advanced colorectal adenoma
Time Frame: Through study completion, an average of 1 year
|
A non-advanced colorectal adenoma is defined as tubular adenoma less than 1cm in diameter.
|
Through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Zhaoshen Li, M.D, study principal investigator
Publications and helpful links
General Publications
- Wang J, Liu S, Wang H, Zheng L, Zhou C, Li G, Huang R, Wang H, Li C, Fan X, Fu X, Wang X, Guo H, Guan J, Sun Y, Song X, Li Z, Mu D, Sun J, Liu X, Qi Y, Niu F, Chen C, Wu X, Wang X, Song X, Zou H. Robust performance of a novel stool DNA test of methylated SDC2 for colorectal cancer detection: a multicenter clinical study. Clin Epigenetics. 2020 Oct 30;12(1):162. doi: 10.1186/s13148-020-00954-x.
- Zhang D, Tang Z, Huang H, Zhou G, Cui C, Weng Y, Liu W, Kim S, Lee S, Perez-Neut M, Ding J, Czyz D, Hu R, Ye Z, He M, Zheng YG, Shuman HA, Dai L, Ren B, Roeder RG, Becker L, Zhao Y. Metabolic regulation of gene expression by histone lactylation. Nature. 2019 Oct;574(7779):575-580. doi: 10.1038/s41586-019-1678-1. Epub 2019 Oct 23.
- Zackular JP, Rogers MA, Ruffin MT 4th, Schloss PD. The human gut microbiome as a screening tool for colorectal cancer. Cancer Prev Res (Phila). 2014 Nov;7(11):1112-21. doi: 10.1158/1940-6207.CAPR-14-0129. Epub 2014 Aug 7.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- multi-omics
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.